Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Retinopathy | 78 | 2025 | 165 | 22.920 |
Why?
|
Angiogenesis Inhibitors | 103 | 2025 | 219 | 19.400 |
Why?
|
Macular Edema | 57 | 2025 | 98 | 15.670 |
Why?
|
Visual Acuity | 110 | 2025 | 843 | 14.030 |
Why?
|
Wet Macular Degeneration | 36 | 2025 | 45 | 10.850 |
Why?
|
Macular Degeneration | 33 | 2025 | 128 | 10.510 |
Why?
|
Ranibizumab | 61 | 2025 | 75 | 10.510 |
Why?
|
Vascular Endothelial Growth Factor A | 89 | 2025 | 444 | 10.080 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 51 | 2024 | 99 | 9.480 |
Why?
|
Intravitreal Injections | 101 | 2025 | 154 | 9.400 |
Why?
|
Tomography, Optical Coherence | 90 | 2025 | 568 | 8.740 |
Why?
|
Recombinant Fusion Proteins | 52 | 2025 | 795 | 8.730 |
Why?
|
Geographic Atrophy | 17 | 2025 | 26 | 7.500 |
Why?
|
Fluorescein Angiography | 68 | 2025 | 152 | 7.380 |
Why?
|
Macula Lutea | 18 | 2025 | 50 | 5.100 |
Why?
|
Retinal Diseases | 18 | 2024 | 179 | 4.900 |
Why?
|
Retinal Detachment | 16 | 2025 | 86 | 4.750 |
Why?
|
Diabetes Mellitus | 19 | 2024 | 931 | 4.670 |
Why?
|
Vitrectomy | 26 | 2025 | 111 | 4.610 |
Why?
|
Antibodies, Monoclonal, Humanized | 23 | 2024 | 555 | 4.390 |
Why?
|
Retinal Vein Occlusion | 17 | 2022 | 28 | 4.380 |
Why?
|
Retinal Vessels | 24 | 2024 | 77 | 4.360 |
Why?
|
Choroidal Neovascularization | 12 | 2023 | 35 | 4.240 |
Why?
|
Retinal Perforations | 10 | 2024 | 27 | 3.680 |
Why?
|
Laser Coagulation | 17 | 2023 | 130 | 3.550 |
Why?
|
Bevacizumab | 20 | 2024 | 78 | 2.930 |
Why?
|
Retina | 22 | 2023 | 498 | 2.530 |
Why?
|
Humans | 249 | 2025 | 133589 | 2.160 |
Why?
|
Aged | 97 | 2025 | 21699 | 2.140 |
Why?
|
Scleral Buckling | 9 | 2022 | 14 | 2.120 |
Why?
|
Choroid | 8 | 2024 | 42 | 2.090 |
Why?
|
Glucocorticoids | 10 | 2024 | 408 | 2.040 |
Why?
|
Middle Aged | 104 | 2025 | 29349 | 2.010 |
Why?
|
Endophthalmitis | 7 | 2016 | 78 | 2.000 |
Why?
|
Follow-Up Studies | 42 | 2025 | 5491 | 1.910 |
Why?
|
Aged, 80 and over | 49 | 2025 | 7203 | 1.790 |
Why?
|
Fundus Oculi | 20 | 2025 | 66 | 1.710 |
Why?
|
Prospective Studies | 48 | 2025 | 6650 | 1.700 |
Why?
|
Male | 123 | 2025 | 65783 | 1.620 |
Why?
|
Treatment Outcome | 58 | 2025 | 13003 | 1.610 |
Why?
|
Photography | 6 | 2022 | 101 | 1.610 |
Why?
|
Female | 128 | 2025 | 71528 | 1.570 |
Why?
|
Peptides, Cyclic | 2 | 2023 | 57 | 1.550 |
Why?
|
Ischemia | 10 | 2021 | 383 | 1.470 |
Why?
|
Vitreous Detachment | 3 | 2024 | 15 | 1.320 |
Why?
|
Retrospective Studies | 58 | 2025 | 17437 | 1.320 |
Why?
|
Complement Inactivating Agents | 4 | 2023 | 12 | 1.310 |
Why?
|
Complement C3 | 4 | 2023 | 54 | 1.260 |
Why?
|
Fovea Centralis | 4 | 2020 | 10 | 1.170 |
Why?
|
Endothelial Growth Factors | 12 | 2023 | 53 | 1.170 |
Why?
|
Eye Infections, Bacterial | 3 | 2016 | 92 | 1.140 |
Why?
|
Retinal Vasculitis | 4 | 2023 | 9 | 1.130 |
Why?
|
Triamcinolone Acetonide | 4 | 2024 | 37 | 1.110 |
Why?
|
Retinal Pigment Epithelium | 5 | 2024 | 37 | 1.110 |
Why?
|
Subretinal Fluid | 7 | 2024 | 11 | 1.060 |
Why?
|
Double-Blind Method | 16 | 2025 | 1669 | 1.060 |
Why?
|
Nerve Fibers | 3 | 2025 | 76 | 0.990 |
Why?
|
Retinal Telangiectasis | 3 | 2025 | 5 | 0.990 |
Why?
|
Epiretinal Membrane | 4 | 2024 | 15 | 0.970 |
Why?
|
Adult | 52 | 2025 | 31933 | 0.940 |
Why?
|
Peripherins | 1 | 2024 | 2 | 0.940 |
Why?
|
Disease Progression | 14 | 2025 | 2238 | 0.890 |
Why?
|
Fluocinolone Acetonide | 4 | 2020 | 7 | 0.890 |
Why?
|
Vitreous Body | 5 | 2024 | 106 | 0.850 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2024 | 196 | 0.840 |
Why?
|
Cysts | 2 | 2024 | 108 | 0.840 |
Why?
|
Retinal Vein | 3 | 2022 | 12 | 0.820 |
Why?
|
Ophthalmology | 6 | 2024 | 200 | 0.820 |
Why?
|
Drug Delivery Systems | 3 | 2025 | 233 | 0.800 |
Why?
|
Angiopoietin-2 | 4 | 2024 | 16 | 0.800 |
Why?
|
Cataract | 3 | 2022 | 227 | 0.790 |
Why?
|
Clinical Trials as Topic | 5 | 2023 | 1153 | 0.790 |
Why?
|
Benchmarking | 1 | 2023 | 148 | 0.780 |
Why?
|
Eye Infections, Fungal | 4 | 2014 | 78 | 0.770 |
Why?
|
Antibodies, Bispecific | 2 | 2024 | 51 | 0.770 |
Why?
|
Edema | 2 | 2022 | 141 | 0.740 |
Why?
|
Carbonic Anhydrases | 11 | 2003 | 26 | 0.720 |
Why?
|
Neovascularization, Pathologic | 7 | 2018 | 258 | 0.710 |
Why?
|
Ophthalmic Solutions | 2 | 2011 | 93 | 0.710 |
Why?
|
Ophthalmoscopy | 3 | 2019 | 29 | 0.700 |
Why?
|
Vision Disorders | 4 | 2023 | 220 | 0.680 |
Why?
|
No-Show Patients | 1 | 2020 | 3 | 0.680 |
Why?
|
Basement Membrane | 5 | 2024 | 49 | 0.670 |
Why?
|
Vitreoretinal Surgery | 2 | 2021 | 7 | 0.670 |
Why?
|
Lost to Follow-Up | 1 | 2020 | 33 | 0.660 |
Why?
|
Retinal Hemorrhage | 2 | 2017 | 26 | 0.660 |
Why?
|
Cataract Extraction | 3 | 2017 | 221 | 0.650 |
Why?
|
Sensory Thresholds | 1 | 2019 | 37 | 0.640 |
Why?
|
Patient Dropouts | 1 | 2019 | 53 | 0.640 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 324 | 0.630 |
Why?
|
Postoperative Complications | 4 | 2017 | 3208 | 0.620 |
Why?
|
Choroid Diseases | 1 | 2019 | 23 | 0.610 |
Why?
|
Time Factors | 12 | 2025 | 6582 | 0.610 |
Why?
|
Eye Diseases | 2 | 2011 | 118 | 0.610 |
Why?
|
Microaneurysm | 3 | 2023 | 3 | 0.580 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 387 | 0.570 |
Why?
|
Retinal Degeneration | 3 | 2025 | 104 | 0.550 |
Why?
|
Lasers | 2 | 2017 | 117 | 0.530 |
Why?
|
Patient Compliance | 1 | 2019 | 480 | 0.510 |
Why?
|
Drug Administration Schedule | 6 | 2022 | 755 | 0.510 |
Why?
|
Biomarkers | 11 | 2025 | 3411 | 0.500 |
Why?
|
Lasers, Solid-State | 1 | 2016 | 19 | 0.500 |
Why?
|
Meningoencephalitis | 1 | 2016 | 21 | 0.500 |
Why?
|
Retinitis | 1 | 2016 | 18 | 0.500 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2024 | 1195 | 0.470 |
Why?
|
Anti-Bacterial Agents | 5 | 2019 | 2511 | 0.470 |
Why?
|
Antibiotic Prophylaxis | 1 | 2016 | 128 | 0.470 |
Why?
|
Silicone Oils | 2 | 2025 | 13 | 0.470 |
Why?
|
Vancomycin | 1 | 2017 | 236 | 0.450 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2018 | 154 | 0.450 |
Why?
|
Cell Hypoxia | 12 | 2004 | 104 | 0.450 |
Why?
|
Povidone-Iodine | 2 | 2011 | 10 | 0.450 |
Why?
|
Clinical Protocols | 5 | 2022 | 244 | 0.450 |
Why?
|
Mutation | 3 | 2025 | 6276 | 0.450 |
Why?
|
Injections, Intraocular | 3 | 2024 | 11 | 0.440 |
Why?
|
West Nile Fever | 1 | 2016 | 139 | 0.430 |
Why?
|
Cryosurgery | 1 | 2013 | 48 | 0.420 |
Why?
|
Fungi | 3 | 2014 | 76 | 0.410 |
Why?
|
Retinal Ganglion Cells | 2 | 2025 | 115 | 0.410 |
Why?
|
Carcinoma, Renal Cell | 4 | 2004 | 251 | 0.410 |
Why?
|
Precision Medicine | 2 | 2018 | 358 | 0.410 |
Why?
|
Atrophy | 6 | 2024 | 250 | 0.400 |
Why?
|
Uveitis | 2 | 2024 | 38 | 0.400 |
Why?
|
Choroid Neoplasms | 2 | 2013 | 26 | 0.390 |
Why?
|
Vitreoretinopathy, Proliferative | 2 | 2022 | 7 | 0.390 |
Why?
|
Transcription Factors | 10 | 2004 | 2704 | 0.380 |
Why?
|
Nuclear Proteins | 9 | 2004 | 1334 | 0.380 |
Why?
|
Antisepsis | 1 | 2011 | 7 | 0.380 |
Why?
|
Mycoses | 2 | 2014 | 121 | 0.370 |
Why?
|
Ophthalmologists | 2 | 2024 | 17 | 0.370 |
Why?
|
Eye | 2 | 2024 | 233 | 0.370 |
Why?
|
Ciliary Body | 1 | 2011 | 32 | 0.360 |
Why?
|
Bacteria | 2 | 2016 | 537 | 0.360 |
Why?
|
Retinal Neovascularization | 3 | 2020 | 16 | 0.360 |
Why?
|
Young Adult | 9 | 2025 | 9897 | 0.360 |
Why?
|
Surgical Wound Infection | 2 | 2017 | 276 | 0.350 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2004 | 384 | 0.350 |
Why?
|
Kidney Neoplasms | 4 | 2004 | 460 | 0.350 |
Why?
|
Endotamponade | 3 | 2025 | 11 | 0.350 |
Why?
|
Retinitis Pigmentosa | 2 | 2025 | 93 | 0.350 |
Why?
|
Tumor Suppressor Proteins | 3 | 2004 | 510 | 0.350 |
Why?
|
Uveal Neoplasms | 1 | 2011 | 61 | 0.350 |
Why?
|
Retreatment | 4 | 2018 | 92 | 0.350 |
Why?
|
Algorithms | 6 | 2024 | 1730 | 0.340 |
Why?
|
Retinal Drusen | 3 | 2024 | 6 | 0.340 |
Why?
|
Aging | 1 | 2018 | 1303 | 0.340 |
Why?
|
Regression Analysis | 3 | 2022 | 832 | 0.340 |
Why?
|
Diagnosis, Differential | 3 | 2024 | 1967 | 0.340 |
Why?
|
Hospitals, University | 1 | 2010 | 104 | 0.340 |
Why?
|
Surgical Flaps | 2 | 2024 | 212 | 0.330 |
Why?
|
Antibodies, Monoclonal | 3 | 2019 | 1070 | 0.330 |
Why?
|
Cephalosporins | 1 | 2011 | 143 | 0.330 |
Why?
|
Neoplasm Proteins | 10 | 2004 | 717 | 0.330 |
Why?
|
Regional Blood Flow | 3 | 2019 | 226 | 0.320 |
Why?
|
Drug Hypersensitivity | 1 | 2011 | 102 | 0.320 |
Why?
|
Pharmaceutical Preparations | 3 | 2023 | 90 | 0.320 |
Why?
|
Monitoring, Intraoperative | 1 | 2010 | 134 | 0.310 |
Why?
|
Cryptococcosis | 1 | 2009 | 44 | 0.310 |
Why?
|
Quality of Life | 4 | 2023 | 2127 | 0.310 |
Why?
|
Oculomotor Nerve | 1 | 2008 | 6 | 0.300 |
Why?
|
DNA-Binding Proteins | 8 | 2004 | 2159 | 0.300 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2008 | 8 | 0.300 |
Why?
|
Capillary Permeability | 2 | 2020 | 77 | 0.300 |
Why?
|
Drug Therapy, Combination | 4 | 2025 | 1200 | 0.300 |
Why?
|
Oculomotor Nerve Diseases | 1 | 2008 | 17 | 0.300 |
Why?
|
Blindness | 2 | 2021 | 79 | 0.300 |
Why?
|
Eye Injuries, Penetrating | 1 | 2008 | 19 | 0.300 |
Why?
|
Risk Factors | 11 | 2024 | 11054 | 0.290 |
Why?
|
Exudates and Transudates | 2 | 2021 | 22 | 0.290 |
Why?
|
Rhabdoid Tumor | 1 | 2008 | 56 | 0.290 |
Why?
|
Adolescent | 7 | 2024 | 20512 | 0.290 |
Why?
|
Antigens, Neoplasm | 8 | 2003 | 407 | 0.280 |
Why?
|
Corneal Ulcer | 1 | 2008 | 57 | 0.280 |
Why?
|
Combined Modality Therapy | 8 | 2020 | 1314 | 0.280 |
Why?
|
Vitelliform Macular Dystrophy | 2 | 2024 | 2 | 0.280 |
Why?
|
Single-Blind Method | 2 | 2021 | 251 | 0.270 |
Why?
|
Teratoma | 1 | 2008 | 130 | 0.270 |
Why?
|
Cross Infection | 1 | 2010 | 331 | 0.270 |
Why?
|
Practice Guidelines as Topic | 3 | 2024 | 1333 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2002 | 2117 | 0.250 |
Why?
|
Severity of Illness Index | 5 | 2021 | 3067 | 0.240 |
Why?
|
Hexokinase | 1 | 2025 | 23 | 0.240 |
Why?
|
Gene Expression Profiling | 2 | 2004 | 1911 | 0.230 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 3739 | 0.230 |
Why?
|
United States | 9 | 2024 | 11654 | 0.230 |
Why?
|
Biomarkers, Tumor | 7 | 2008 | 1716 | 0.230 |
Why?
|
Intraocular Pressure | 2 | 2024 | 146 | 0.230 |
Why?
|
Melanoma | 2 | 2013 | 976 | 0.230 |
Why?
|
Aqueous Humor | 2 | 2022 | 28 | 0.220 |
Why?
|
Oxygen | 6 | 2018 | 577 | 0.220 |
Why?
|
Keratomileusis, Laser In Situ | 1 | 2006 | 149 | 0.220 |
Why?
|
Angiopoietins | 2 | 2021 | 21 | 0.220 |
Why?
|
Drug Approval | 1 | 2024 | 45 | 0.220 |
Why?
|
Myopia | 1 | 2006 | 194 | 0.220 |
Why?
|
Complement C5 | 1 | 2023 | 7 | 0.220 |
Why?
|
Cross-Over Studies | 1 | 2025 | 331 | 0.220 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2002 | 73 | 0.220 |
Why?
|
Ligases | 2 | 2000 | 48 | 0.220 |
Why?
|
Cyclin D1 | 1 | 2004 | 123 | 0.220 |
Why?
|
Hypoxia | 4 | 2004 | 262 | 0.220 |
Why?
|
Tumor Cells, Cultured | 9 | 2004 | 1101 | 0.210 |
Why?
|
Entropy | 1 | 2023 | 29 | 0.210 |
Why?
|
United States Food and Drug Administration | 1 | 2024 | 158 | 0.210 |
Why?
|
Meta-Analysis as Topic | 1 | 2024 | 172 | 0.210 |
Why?
|
Biosimilar Pharmaceuticals | 1 | 2023 | 6 | 0.210 |
Why?
|
Photochemotherapy | 2 | 2022 | 48 | 0.210 |
Why?
|
Aptamers, Nucleotide | 1 | 2023 | 33 | 0.210 |
Why?
|
Drainage | 1 | 2025 | 265 | 0.210 |
Why?
|
Evidence-Based Medicine | 2 | 2024 | 667 | 0.210 |
Why?
|
Traction | 1 | 2022 | 9 | 0.200 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 9 | 2004 | 104 | 0.200 |
Why?
|
Drug Resistance | 2 | 2013 | 263 | 0.200 |
Why?
|
Eye Neoplasms | 2 | 2013 | 52 | 0.200 |
Why?
|
Prone Position | 1 | 2022 | 33 | 0.190 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2022 | 6 | 0.190 |
Why?
|
Hypoxia-Inducible Factor 1 | 8 | 2004 | 19 | 0.190 |
Why?
|
Porphyrins | 1 | 2022 | 18 | 0.190 |
Why?
|
Delphi Technique | 1 | 2023 | 243 | 0.190 |
Why?
|
Polyethylene Glycols | 1 | 2023 | 251 | 0.190 |
Why?
|
Imaging, Three-Dimensional | 1 | 2024 | 396 | 0.190 |
Why?
|
Biomedical Research | 2 | 2019 | 555 | 0.190 |
Why?
|
Equipment Design | 2 | 2020 | 611 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2012 | 383 | 0.180 |
Why?
|
Confidence Intervals | 1 | 2021 | 301 | 0.180 |
Why?
|
Postoperative Period | 2 | 2020 | 348 | 0.180 |
Why?
|
Blood-Retinal Barrier | 2 | 2020 | 3 | 0.180 |
Why?
|
Drug Implants | 2 | 2020 | 44 | 0.180 |
Why?
|
Computer Systems | 1 | 2021 | 38 | 0.180 |
Why?
|
Cornea | 1 | 2006 | 681 | 0.170 |
Why?
|
Registries | 3 | 2023 | 1557 | 0.170 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2020 | 1734 | 0.170 |
Why?
|
Videoconferencing | 1 | 2020 | 22 | 0.170 |
Why?
|
Cytokines | 3 | 2022 | 1397 | 0.170 |
Why?
|
Surgery, Computer-Assisted | 2 | 2020 | 65 | 0.170 |
Why?
|
Patient Reported Outcome Measures | 1 | 2022 | 203 | 0.160 |
Why?
|
Fractals | 1 | 2019 | 2 | 0.160 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 20 | 0.160 |
Why?
|
Consensus | 1 | 2023 | 732 | 0.160 |
Why?
|
Microcirculation | 2 | 2019 | 118 | 0.160 |
Why?
|
Recurrence | 3 | 2019 | 1470 | 0.160 |
Why?
|
Income | 1 | 2020 | 141 | 0.160 |
Why?
|
Congresses as Topic | 1 | 2020 | 187 | 0.160 |
Why?
|
Biological Products | 1 | 2021 | 140 | 0.150 |
Why?
|
Insurance Coverage | 1 | 2020 | 124 | 0.150 |
Why?
|
Early Diagnosis | 1 | 2019 | 199 | 0.150 |
Why?
|
Longitudinal Studies | 2 | 2022 | 1485 | 0.150 |
Why?
|
Delayed-Action Preparations | 1 | 2018 | 122 | 0.150 |
Why?
|
Antifungal Agents | 3 | 2014 | 309 | 0.150 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 154 | 0.150 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 565 | 0.150 |
Why?
|
Necrosis | 7 | 2004 | 221 | 0.140 |
Why?
|
Vision, Low | 1 | 2017 | 14 | 0.140 |
Why?
|
Visual Prosthesis | 1 | 2017 | 6 | 0.140 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 103 | 0.140 |
Why?
|
Proteins | 2 | 2000 | 1088 | 0.140 |
Why?
|
Ultrasonography | 3 | 2024 | 992 | 0.140 |
Why?
|
Breast Neoplasms | 5 | 2004 | 2769 | 0.140 |
Why?
|
Betacoronavirus | 1 | 2020 | 309 | 0.130 |
Why?
|
Drug and Narcotic Control | 1 | 2016 | 17 | 0.130 |
Why?
|
Legislation, Drug | 1 | 2016 | 9 | 0.130 |
Why?
|
Prosthesis Implantation | 1 | 2017 | 146 | 0.130 |
Why?
|
Beryllium | 1 | 2016 | 3 | 0.130 |
Why?
|
Administration, Topical | 1 | 2016 | 143 | 0.130 |
Why?
|
Cohort Studies | 6 | 2022 | 5180 | 0.120 |
Why?
|
Genes, Tumor Suppressor | 3 | 2002 | 225 | 0.120 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 13 | 0.120 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 471 | 0.120 |
Why?
|
Photoreceptor Cells, Vertebrate | 1 | 2015 | 41 | 0.120 |
Why?
|
Coronavirus Infections | 1 | 2020 | 388 | 0.120 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 399 | 0.110 |
Why?
|
Lung Neoplasms | 4 | 2012 | 1796 | 0.110 |
Why?
|
Medication Adherence | 1 | 2018 | 339 | 0.110 |
Why?
|
Vascular Endothelial Growth Factors | 3 | 2023 | 53 | 0.110 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2004 | 37 | 0.110 |
Why?
|
Fluconazole | 2 | 2014 | 50 | 0.110 |
Why?
|
Amphotericin B | 2 | 2014 | 93 | 0.110 |
Why?
|
von Hippel-Lindau Disease | 3 | 2002 | 20 | 0.100 |
Why?
|
History, 18th Century | 1 | 2013 | 70 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2019 | 766 | 0.100 |
Why?
|
Electronic Health Records | 1 | 2020 | 790 | 0.100 |
Why?
|
Carbonic Anhydrase IX | 8 | 2003 | 13 | 0.100 |
Why?
|
Observational Studies as Topic | 2 | 2023 | 102 | 0.100 |
Why?
|
Anterior Chamber | 1 | 2012 | 58 | 0.090 |
Why?
|
Electroretinography | 2 | 2025 | 123 | 0.090 |
Why?
|
Chlorhexidine | 1 | 2011 | 47 | 0.090 |
Why?
|
Blood Glucose | 1 | 2016 | 1194 | 0.090 |
Why?
|
Telemedicine | 1 | 2018 | 498 | 0.090 |
Why?
|
Lymphokines | 2 | 2002 | 69 | 0.090 |
Why?
|
Drug Costs | 1 | 2011 | 67 | 0.090 |
Why?
|
Liver Function Tests | 1 | 2011 | 107 | 0.090 |
Why?
|
Retinopathy of Prematurity | 1 | 2011 | 61 | 0.090 |
Why?
|
Age Factors | 1 | 2018 | 2977 | 0.090 |
Why?
|
Glucose | 1 | 2015 | 924 | 0.090 |
Why?
|
Refraction, Ocular | 1 | 2013 | 312 | 0.090 |
Why?
|
Laser Therapy | 1 | 2013 | 252 | 0.090 |
Why?
|
Florida | 1 | 2010 | 79 | 0.080 |
Why?
|
Decision Making | 1 | 2015 | 695 | 0.080 |
Why?
|
Acute Disease | 2 | 2010 | 1185 | 0.080 |
Why?
|
Penicillins | 1 | 2011 | 155 | 0.080 |
Why?
|
Prognosis | 7 | 2024 | 5073 | 0.080 |
Why?
|
Signal Transduction | 3 | 2021 | 4889 | 0.080 |
Why?
|
Neoplasms | 2 | 2004 | 3012 | 0.080 |
Why?
|
Flucytosine | 1 | 2009 | 17 | 0.080 |
Why?
|
Child | 3 | 2024 | 25711 | 0.080 |
Why?
|
Cryptococcus neoformans | 1 | 2009 | 23 | 0.080 |
Why?
|
Immunohistochemistry | 6 | 2003 | 1760 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2021 | 77 | 0.080 |
Why?
|
In Situ Hybridization | 4 | 2004 | 484 | 0.080 |
Why?
|
Intraoperative Complications | 1 | 2010 | 175 | 0.080 |
Why?
|
Meningeal Carcinomatosis | 1 | 2008 | 4 | 0.080 |
Why?
|
Preoperative Care | 1 | 2011 | 371 | 0.080 |
Why?
|
Diagnostic Imaging | 1 | 2011 | 312 | 0.080 |
Why?
|
Subarachnoid Space | 1 | 2008 | 25 | 0.080 |
Why?
|
Mesencephalon | 1 | 2008 | 38 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2008 | 664 | 0.070 |
Why?
|
Eye Enucleation | 1 | 2008 | 54 | 0.070 |
Why?
|
Incidence | 1 | 2016 | 3386 | 0.070 |
Why?
|
Keratoplasty, Penetrating | 1 | 2008 | 54 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2008 | 372 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2020 | 3062 | 0.070 |
Why?
|
Treatment Failure | 1 | 2008 | 361 | 0.070 |
Why?
|
Blotting, Western | 4 | 2003 | 1138 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2001 | 874 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2024 | 3632 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2002 | 553 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2006 | 45 | 0.060 |
Why?
|
Capillaries | 2 | 2017 | 69 | 0.060 |
Why?
|
Neurosurgical Procedures | 1 | 2008 | 321 | 0.060 |
Why?
|
Head and Neck Neoplasms | 2 | 2001 | 693 | 0.060 |
Why?
|
Hydrocephalus | 1 | 2008 | 274 | 0.060 |
Why?
|
Pilot Projects | 2 | 2020 | 1488 | 0.060 |
Why?
|
Transfection | 3 | 2004 | 1090 | 0.060 |
Why?
|
Phenotype | 3 | 2025 | 4527 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 3840 | 0.060 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 3 | 2003 | 406 | 0.060 |
Why?
|
Immunoblotting | 2 | 2004 | 317 | 0.060 |
Why?
|
Suspensions | 1 | 2024 | 10 | 0.060 |
Why?
|
Search Engine | 1 | 2023 | 7 | 0.050 |
Why?
|
Pandemics | 2 | 2023 | 1191 | 0.050 |
Why?
|
Organic Chemicals | 1 | 2023 | 60 | 0.050 |
Why?
|
Plasmids | 2 | 2004 | 525 | 0.050 |
Why?
|
Vitreous Hemorrhage | 1 | 2023 | 9 | 0.050 |
Why?
|
RNA, Messenger | 4 | 2004 | 2898 | 0.050 |
Why?
|
Equivalence Trials as Topic | 1 | 2023 | 14 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2023 | 10 | 0.050 |
Why?
|
Inflammation | 2 | 2022 | 1601 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2025 | 839 | 0.050 |
Why?
|
Nephrons | 1 | 2002 | 21 | 0.050 |
Why?
|
Neurofibromin 2 | 1 | 2022 | 11 | 0.050 |
Why?
|
Indocyanine Green | 2 | 2015 | 63 | 0.050 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2002 | 25 | 0.050 |
Why?
|
Syringes | 1 | 2022 | 25 | 0.050 |
Why?
|
Cell Division | 2 | 2001 | 773 | 0.050 |
Why?
|
Up-Regulation | 2 | 2004 | 907 | 0.050 |
Why?
|
Photosensitizing Agents | 1 | 2022 | 43 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 240 | 0.050 |
Why?
|
Pentosan Sulfuric Polyester | 1 | 2021 | 1 | 0.050 |
Why?
|
Cell Adhesion Molecule-1 | 1 | 2021 | 1 | 0.050 |
Why?
|
Monocyte Chemoattractant Proteins | 1 | 2021 | 9 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2008 | 1313 | 0.050 |
Why?
|
Canada | 1 | 2022 | 343 | 0.050 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2021 | 29 | 0.050 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2021 | 39 | 0.050 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 40 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 2166 | 0.040 |
Why?
|
Pedigree | 1 | 2025 | 1694 | 0.040 |
Why?
|
Genetic Association Studies | 1 | 2025 | 843 | 0.040 |
Why?
|
Helix-Loop-Helix Motifs | 1 | 2001 | 43 | 0.040 |
Why?
|
RNA | 2 | 2004 | 601 | 0.040 |
Why?
|
Ribonucleases | 1 | 2000 | 51 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2002 | 1069 | 0.040 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2000 | 27 | 0.040 |
Why?
|
Iatrogenic Disease | 1 | 2021 | 136 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1358 | 0.040 |
Why?
|
Machine Learning | 1 | 2024 | 327 | 0.040 |
Why?
|
Extracellular Space | 1 | 2001 | 90 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2001 | 91 | 0.040 |
Why?
|
Antigens, Nuclear | 1 | 2001 | 57 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 289 | 0.040 |
Why?
|
Organ Size | 1 | 2022 | 468 | 0.040 |
Why?
|
Slit Lamp Microscopy | 1 | 2020 | 5 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2001 | 206 | 0.040 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2002 | 283 | 0.040 |
Why?
|
Nitroimidazoles | 1 | 2000 | 44 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2011 | 1407 | 0.040 |
Why?
|
Half-Life | 1 | 2020 | 160 | 0.040 |
Why?
|
Observation | 1 | 2020 | 45 | 0.040 |
Why?
|
Erythropoietin | 1 | 2001 | 110 | 0.040 |
Why?
|
Trans-Activators | 2 | 2001 | 827 | 0.040 |
Why?
|
Homeodomain Proteins | 1 | 2003 | 585 | 0.040 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2019 | 64 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2001 | 427 | 0.040 |
Why?
|
Genes, Reporter | 1 | 2000 | 394 | 0.040 |
Why?
|
Breast | 1 | 2001 | 219 | 0.040 |
Why?
|
Calcinosis | 1 | 2001 | 194 | 0.040 |
Why?
|
Promoter Regions, Genetic | 2 | 2000 | 1413 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2004 | 867 | 0.040 |
Why?
|
Medicare | 1 | 2023 | 464 | 0.040 |
Why?
|
Genetic Therapy | 1 | 2024 | 727 | 0.040 |
Why?
|
Protein Binding | 2 | 2020 | 1831 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2021 | 453 | 0.040 |
Why?
|
Cells | 1 | 1999 | 25 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 235 | 0.040 |
Why?
|
Genotype | 1 | 2025 | 2805 | 0.040 |
Why?
|
Gene Expression Regulation | 4 | 2004 | 2661 | 0.040 |
Why?
|
Specialization | 1 | 2019 | 82 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2002 | 695 | 0.040 |
Why?
|
Research Design | 1 | 2023 | 757 | 0.040 |
Why?
|
Expert Testimony | 1 | 2018 | 37 | 0.040 |
Why?
|
Quality Improvement | 1 | 2024 | 687 | 0.040 |
Why?
|
Anesthetics, Local | 1 | 2019 | 91 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2019 | 292 | 0.040 |
Why?
|
Hemorrhage | 1 | 2021 | 505 | 0.040 |
Why?
|
Carcinoma | 1 | 2000 | 322 | 0.040 |
Why?
|
Caveolins | 1 | 1997 | 15 | 0.040 |
Why?
|
Models, Genetic | 1 | 2000 | 789 | 0.030 |
Why?
|
Multimodal Imaging | 1 | 2018 | 129 | 0.030 |
Why?
|
European Union | 1 | 2016 | 13 | 0.030 |
Why?
|
Infant | 2 | 2011 | 13123 | 0.030 |
Why?
|
Emergency Medical Services | 1 | 2021 | 415 | 0.030 |
Why?
|
Anticoagulants | 1 | 2021 | 598 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2024 | 2221 | 0.030 |
Why?
|
Gene Expression | 1 | 2001 | 1615 | 0.030 |
Why?
|
Internet | 1 | 2019 | 398 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 866 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2022 | 676 | 0.030 |
Why?
|
Drug Substitution | 1 | 2015 | 22 | 0.030 |
Why?
|
Voriconazole | 1 | 2014 | 35 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2017 | 710 | 0.030 |
Why?
|
COS Cells | 2 | 2004 | 283 | 0.030 |
Why?
|
Logistic Models | 1 | 2019 | 1907 | 0.030 |
Why?
|
Survival Analysis | 3 | 2003 | 1599 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1997 | 645 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 1997 | 1439 | 0.030 |
Why?
|
Visual Fields | 1 | 2014 | 138 | 0.030 |
Why?
|
Observer Variation | 1 | 2014 | 313 | 0.030 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 282 | 0.030 |
Why?
|
Light Coagulation | 1 | 2013 | 24 | 0.030 |
Why?
|
RNA, Neoplasm | 2 | 2004 | 144 | 0.030 |
Why?
|
Nevus | 1 | 2013 | 36 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2000 | 906 | 0.030 |
Why?
|
Hyperthermia, Induced | 1 | 2013 | 58 | 0.030 |
Why?
|
Immunoenzyme Techniques | 2 | 2002 | 260 | 0.020 |
Why?
|
Hemangioma | 1 | 2013 | 97 | 0.020 |
Why?
|
Child, Preschool | 2 | 2022 | 14762 | 0.020 |
Why?
|
Mass Screening | 1 | 2018 | 832 | 0.020 |
Why?
|
Retinoblastoma | 1 | 2013 | 119 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2014 | 398 | 0.020 |
Why?
|
Retinal Neoplasms | 1 | 2013 | 104 | 0.020 |
Why?
|
Radiation Injuries | 1 | 2013 | 164 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 72 | 0.020 |
Why?
|
Enzyme Induction | 2 | 2001 | 105 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2014 | 828 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2019 | 862 | 0.020 |
Why?
|
Prevalence | 1 | 2016 | 2653 | 0.020 |
Why?
|
Coloring Agents | 1 | 2009 | 81 | 0.020 |
Why?
|
Fluorescence | 1 | 2009 | 103 | 0.020 |
Why?
|
Membrane Proteins | 1 | 1997 | 1610 | 0.020 |
Why?
|
Response Elements | 2 | 1999 | 106 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 1403 | 0.020 |
Why?
|
Syndrome | 1 | 2009 | 1148 | 0.020 |
Why?
|
Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2004 | 22 | 0.010 |
Why?
|
Procollagen-Proline Dioxygenase | 1 | 2004 | 36 | 0.010 |
Why?
|
Immune Sera | 1 | 2004 | 95 | 0.010 |
Why?
|
Mixed Function Oxygenases | 1 | 2004 | 35 | 0.010 |
Why?
|
Immediate-Early Proteins | 1 | 2004 | 60 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2004 | 404 | 0.010 |
Why?
|
Doxycycline | 1 | 2004 | 121 | 0.010 |
Why?
|
Survival | 1 | 2003 | 20 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2004 | 337 | 0.010 |
Why?
|
Animals | 5 | 2004 | 36308 | 0.010 |
Why?
|
Apoptosis | 2 | 2002 | 1933 | 0.010 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2002 | 33 | 0.010 |
Why?
|
Glucose Transporter Type 1 | 1 | 2002 | 26 | 0.010 |
Why?
|
RNA Probes | 1 | 2002 | 31 | 0.010 |
Why?
|
RNA Interference | 1 | 2004 | 544 | 0.010 |
Why?
|
Isoenzymes | 1 | 2003 | 232 | 0.010 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2002 | 43 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 2002 | 130 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2004 | 714 | 0.010 |
Why?
|
Down-Regulation | 1 | 2004 | 715 | 0.010 |
Why?
|
Thymidine Phosphorylase | 1 | 2001 | 13 | 0.010 |
Why?
|
Mucin-1 | 1 | 2001 | 37 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2004 | 1086 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2001 | 55 | 0.010 |
Why?
|
DNA Primers | 1 | 2002 | 671 | 0.010 |
Why?
|
England | 1 | 2001 | 72 | 0.010 |
Why?
|
Drug Therapy | 1 | 2001 | 93 | 0.010 |
Why?
|
Protein Kinases | 1 | 2002 | 342 | 0.010 |
Why?
|
Nephrectomy | 1 | 2002 | 181 | 0.010 |
Why?
|
Radiotherapy | 1 | 2001 | 151 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 520 | 0.010 |
Why?
|
Antigens, CD | 1 | 2002 | 452 | 0.010 |
Why?
|
ErbB Receptors | 1 | 2001 | 303 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1326 | 0.010 |
Why?
|
Mice | 3 | 2004 | 18845 | 0.010 |
Why?
|
Cobalt | 1 | 1999 | 18 | 0.010 |
Why?
|
Iron Chelating Agents | 1 | 1999 | 15 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2003 | 1490 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2001 | 973 | 0.010 |
Why?
|
Cell Line | 1 | 2004 | 2843 | 0.010 |
Why?
|
Multienzyme Complexes | 1 | 1999 | 88 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2002 | 619 | 0.010 |
Why?
|
Cysteine Endopeptidases | 1 | 1999 | 119 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2004 | 1756 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2011 | 8572 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 1999 | 270 | 0.010 |
Why?
|
Receptor, ErbB-2 | 1 | 2001 | 560 | 0.010 |
Why?
|
Survival Rate | 1 | 2003 | 2204 | 0.010 |
Why?
|
Genes, fos | 1 | 1997 | 15 | 0.010 |
Why?
|
Mammals | 1 | 1999 | 277 | 0.010 |
Why?
|
3T3 Cells | 1 | 1997 | 123 | 0.010 |
Why?
|
Caveolin 1 | 1 | 1997 | 50 | 0.010 |
Why?
|
HeLa Cells | 1 | 1999 | 827 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2002 | 1061 | 0.010 |
Why?
|
Genes, ras | 1 | 1997 | 101 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2001 | 1403 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2001 | 821 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2001 | 2307 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 1997 | 496 | 0.010 |
Why?
|
Lung | 1 | 2003 | 1562 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2001 | 1074 | 0.010 |
Why?
|